Salient Pharmaceuticals is currently sponsoring a clinical study using all-natural CASAD™ to treat metastatic colorectal cancer patients receiving irinotecan® alone or in combination with other therapies. Salient has selected this trial as its first study because of the significant incidence of severe diarrhea associated with irinotecan treatment and the fact that diarrhea is the treatment regimen’s dose-limiting side effect. At this time there are no preventative medications to stop diarrhea from occurring and the available treatments may not be effective for many patients.
The clinical study is being conducted at the University of Texas MD Anderson Cancer Center and several other leading oncology clinics around the nation. If you are a colorectal cancer patient receiving or scheduled to receive irinotecan, you may be eligible for the trial if you are being treated at one of the sites listed below and you meet the study criteria. If the clinical study is available in your area and you believe you may qualify, please contact your doctor for more information.
Atlanta Regional Community Clinical Oncology Program, a Division of Saint Joseph's Hospital of Atlanta, Inc.
Decatur Memorial Hospital
Christus St. Frances Cabrini Hospital
West Michigan Cancer Center
Ozark Health Ventures dba Cancer Research for the Ozarks (CoxHealth)
Columbia River Oncology Program
Main Line Hospitals, Inc.
Greenville Hospital System University Medical Center
Spartanburg Regional Medical Center
Meharry Medical College
M.D. Anderson Cancer Center
Scott and White Hospital